# A Study of TQ05105 Tablets in Subjects With Hemophagocytic Lymphohistiocytosis（HLH）

> **NCT04326348** · PHASE1 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Hemophagocytic Lymphohistiocytosis

## Interventions

- **DRUG:** TQ05105

## Key facts

- **NCT ID:** NCT04326348
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-17
- **Primary completion:** 2022-01
- **Final completion:** 2022-07
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2020-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04326348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04326348, "A Study of TQ05105 Tablets in Subjects With Hemophagocytic Lymphohistiocytosis（HLH）". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04326348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*